| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 12 | 2024 | 302 | 3.430 |
Why?
|
| Magnetic Resonance Imaging | 23 | 2024 | 2057 | 2.970 |
Why?
|
| Glioblastoma | 10 | 2024 | 155 | 2.770 |
Why?
|
| Glioma | 7 | 2024 | 99 | 2.290 |
Why?
|
| Lumbar Vertebrae | 4 | 2024 | 137 | 1.970 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2024 | 1513 | 1.770 |
Why?
|
| Brain | 16 | 2023 | 1488 | 1.440 |
Why?
|
| Pneumonia, Viral | 4 | 2021 | 205 | 1.380 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 192 | 1.240 |
Why?
|
| Central Nervous System Neoplasms | 8 | 2022 | 38 | 0.990 |
Why?
|
| Oculomotor Muscles | 2 | 2016 | 10 | 0.960 |
Why?
|
| Dextrans | 4 | 2014 | 45 | 0.920 |
Why?
|
| Magnetite Nanoparticles | 4 | 2014 | 28 | 0.920 |
Why?
|
| Neuroimaging | 4 | 2024 | 144 | 0.900 |
Why?
|
| Betacoronavirus | 3 | 2020 | 166 | 0.900 |
Why?
|
| Cauda Equina | 1 | 2023 | 7 | 0.880 |
Why?
|
| Olfaction Disorders | 2 | 2021 | 11 | 0.880 |
Why?
|
| Weight-Bearing | 1 | 2023 | 35 | 0.870 |
Why?
|
| Sarcopenia | 2 | 2020 | 18 | 0.870 |
Why?
|
| Humans | 76 | 2024 | 59454 | 0.850 |
Why?
|
| Connectome | 1 | 2023 | 29 | 0.850 |
Why?
|
| Neurosurgery | 1 | 2023 | 28 | 0.850 |
Why?
|
| Spinal Stenosis | 1 | 2023 | 26 | 0.850 |
Why?
|
| Lymphoma | 7 | 2022 | 99 | 0.850 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2023 | 19 | 0.840 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 3 | 2014 | 145 | 0.820 |
Why?
|
| Crohn Disease | 1 | 2024 | 106 | 0.800 |
Why?
|
| Infection Control | 2 | 2020 | 95 | 0.790 |
Why?
|
| Image Enhancement | 2 | 2020 | 188 | 0.770 |
Why?
|
| Pandemics | 4 | 2020 | 617 | 0.750 |
Why?
|
| Contrast Media | 5 | 2020 | 404 | 0.730 |
Why?
|
| Epidural Abscess | 1 | 2021 | 9 | 0.720 |
Why?
|
| Health Facility Planning | 1 | 2021 | 2 | 0.720 |
Why?
|
| Disinfection | 1 | 2020 | 20 | 0.670 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 21 | 0.670 |
Why?
|
| Radiology Department, Hospital | 1 | 2020 | 23 | 0.660 |
Why?
|
| Optical Imaging | 1 | 2020 | 68 | 0.650 |
Why?
|
| Stem Cell Transplantation | 6 | 2017 | 75 | 0.640 |
Why?
|
| Fluorescent Dyes | 1 | 2020 | 196 | 0.620 |
Why?
|
| Leukodystrophy, Metachromatic | 1 | 2018 | 3 | 0.610 |
Why?
|
| Homocystinuria | 1 | 2018 | 4 | 0.610 |
Why?
|
| Italy | 8 | 2024 | 63 | 0.570 |
Why?
|
| Occupational Exposure | 1 | 2020 | 307 | 0.540 |
Why?
|
| Cerebellum | 2 | 2016 | 91 | 0.540 |
Why?
|
| Microglia | 4 | 2019 | 230 | 0.540 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2022 | 328 | 0.540 |
Why?
|
| Graves Ophthalmopathy | 2 | 2014 | 6 | 0.530 |
Why?
|
| Reproducibility of Results | 6 | 2024 | 1560 | 0.530 |
Why?
|
| Ocular Motility Disorders | 1 | 2016 | 2 | 0.520 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2016 | 10 | 0.510 |
Why?
|
| Retrospective Studies | 12 | 2024 | 6079 | 0.500 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2022 | 402 | 0.500 |
Why?
|
| Female | 40 | 2024 | 30766 | 0.500 |
Why?
|
| Eye Movements | 1 | 2016 | 82 | 0.480 |
Why?
|
| Prognosis | 8 | 2022 | 1597 | 0.470 |
Why?
|
| Stroke | 3 | 2021 | 1128 | 0.470 |
Why?
|
| Neurons | 5 | 2018 | 864 | 0.460 |
Why?
|
| Cell Tracking | 1 | 2014 | 7 | 0.450 |
Why?
|
| Endovascular Procedures | 1 | 2021 | 609 | 0.450 |
Why?
|
| Cadaver | 2 | 2024 | 110 | 0.440 |
Why?
|
| Neovascularization, Pathologic | 5 | 2020 | 137 | 0.440 |
Why?
|
| Adult | 24 | 2024 | 15697 | 0.430 |
Why?
|
| Positron-Emission Tomography | 7 | 2024 | 200 | 0.420 |
Why?
|
| Orbital Neoplasms | 2 | 2010 | 6 | 0.420 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 3 | 2018 | 57 | 0.400 |
Why?
|
| Neoplasms | 2 | 2020 | 1232 | 0.400 |
Why?
|
| Middle Aged | 27 | 2024 | 16335 | 0.390 |
Why?
|
| Aged | 20 | 2024 | 13424 | 0.390 |
Why?
|
| Mice | 22 | 2024 | 10301 | 0.390 |
Why?
|
| Male | 34 | 2024 | 27784 | 0.390 |
Why?
|
| Neurosurgical Procedures | 4 | 2024 | 95 | 0.380 |
Why?
|
| DNA Modification Methylases | 2 | 2021 | 18 | 0.360 |
Why?
|
| DNA Repair Enzymes | 2 | 2021 | 37 | 0.350 |
Why?
|
| Animals | 25 | 2024 | 19667 | 0.350 |
Why?
|
| Methotrexate | 5 | 2022 | 76 | 0.350 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2010 | 65 | 0.330 |
Why?
|
| Tonic Pupil | 1 | 2009 | 1 | 0.320 |
Why?
|
| Dermoscopy | 1 | 2009 | 11 | 0.320 |
Why?
|
| Stem Cells | 3 | 2007 | 255 | 0.310 |
Why?
|
| DNA Methylation | 2 | 2021 | 272 | 0.310 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 4 | 2012 | 9 | 0.300 |
Why?
|
| Combined Modality Therapy | 7 | 2022 | 354 | 0.300 |
Why?
|
| Antineoplastic Agents | 3 | 2010 | 628 | 0.290 |
Why?
|
| Neurodegenerative Diseases | 2 | 2023 | 134 | 0.290 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 836 | 0.280 |
Why?
|
| Neoplastic Stem Cells | 4 | 2019 | 196 | 0.280 |
Why?
|
| Eye Neoplasms | 3 | 2013 | 17 | 0.280 |
Why?
|
| T-Lymphocytes | 1 | 2012 | 986 | 0.280 |
Why?
|
| Rituximab | 5 | 2022 | 80 | 0.270 |
Why?
|
| Cell Line, Tumor | 7 | 2020 | 1368 | 0.270 |
Why?
|
| Quinolines | 2 | 2018 | 41 | 0.260 |
Why?
|
| Disease Models, Animal | 9 | 2020 | 2051 | 0.250 |
Why?
|
| Lymphoma, B-Cell | 3 | 2016 | 59 | 0.250 |
Why?
|
| Reference Standards | 1 | 2024 | 71 | 0.230 |
Why?
|
| Iduronate Sulfatase | 1 | 2024 | 2 | 0.220 |
Why?
|
| Leukocyte L1 Antigen Complex | 1 | 2024 | 5 | 0.220 |
Why?
|
| Cytarabine | 4 | 2022 | 32 | 0.220 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2024 | 20 | 0.220 |
Why?
|
| Choroid Plexus | 1 | 2024 | 16 | 0.220 |
Why?
|
| Intranuclear Inclusion Bodies | 1 | 2023 | 8 | 0.220 |
Why?
|
| Mucopolysaccharidosis II | 1 | 2024 | 10 | 0.220 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2024 | 19 | 0.220 |
Why?
|
| Spinal Nerve Roots | 1 | 2023 | 17 | 0.220 |
Why?
|
| Permeability | 1 | 2024 | 49 | 0.220 |
Why?
|
| Thorax | 1 | 2023 | 34 | 0.210 |
Why?
|
| Prospective Studies | 5 | 2024 | 3072 | 0.210 |
Why?
|
| C-Reactive Protein | 1 | 2024 | 159 | 0.210 |
Why?
|
| Thiotepa | 3 | 2022 | 5 | 0.200 |
Why?
|
| Oligodendroglioma | 1 | 2022 | 7 | 0.200 |
Why?
|
| Epilepsy | 1 | 2024 | 105 | 0.200 |
Why?
|
| Quadriplegia | 2 | 2021 | 14 | 0.200 |
Why?
|
| Astrocytoma | 1 | 2022 | 12 | 0.200 |
Why?
|
| Pneumothorax | 1 | 2023 | 49 | 0.200 |
Why?
|
| Language | 1 | 2023 | 133 | 0.200 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2020 | 490 | 0.200 |
Why?
|
| Isoquinolines | 2 | 2015 | 32 | 0.190 |
Why?
|
| Re-Irradiation | 1 | 2021 | 2 | 0.190 |
Why?
|
| Skull Base Neoplasms | 1 | 2021 | 5 | 0.190 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 140 | 0.190 |
Why?
|
| Meningeal Neoplasms | 1 | 2021 | 58 | 0.180 |
Why?
|
| Meningioma | 1 | 2021 | 59 | 0.180 |
Why?
|
| Severity of Illness Index | 2 | 2024 | 1482 | 0.180 |
Why?
|
| Trigeminal Nerve | 1 | 2021 | 5 | 0.180 |
Why?
|
| Radiation Injuries | 1 | 2021 | 62 | 0.180 |
Why?
|
| Nervous System Diseases | 2 | 2017 | 104 | 0.180 |
Why?
|
| Lysosomal Storage Diseases, Nervous System | 2 | 2012 | 2 | 0.180 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2019 | 50 | 0.180 |
Why?
|
| World Health Organization | 1 | 2021 | 30 | 0.180 |
Why?
|
| Doxycycline | 3 | 2012 | 42 | 0.180 |
Why?
|
| Temporal Muscle | 1 | 2020 | 2 | 0.180 |
Why?
|
| Fluorine Radioisotopes | 2 | 2018 | 7 | 0.180 |
Why?
|
| Rats | 3 | 2020 | 1911 | 0.180 |
Why?
|
| Biomarkers | 2 | 2024 | 1306 | 0.180 |
Why?
|
| Exanthema | 1 | 2021 | 26 | 0.180 |
Why?
|
| Methylation | 1 | 2021 | 125 | 0.180 |
Why?
|
| Child | 3 | 2023 | 4201 | 0.180 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2020 | 1 | 0.180 |
Why?
|
| Endothelial Cells | 2 | 2020 | 173 | 0.180 |
Why?
|
| Multiple Sclerosis | 2 | 2018 | 207 | 0.180 |
Why?
|
| Watchful Waiting | 1 | 2020 | 24 | 0.170 |
Why?
|
| Therapeutic Irrigation | 1 | 2020 | 14 | 0.170 |
Why?
|
| Rhabdomyosarcoma | 1 | 2020 | 16 | 0.170 |
Why?
|
| Rotator Cuff Injuries | 1 | 2020 | 8 | 0.170 |
Why?
|
| Shoulder Pain | 1 | 2020 | 12 | 0.170 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2024 | 651 | 0.170 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2020 | 31 | 0.170 |
Why?
|
| Chlamydophila psittaci | 2 | 2012 | 2 | 0.170 |
Why?
|
| Psittacosis | 2 | 2012 | 2 | 0.170 |
Why?
|
| Cervical Vertebrae | 1 | 2021 | 101 | 0.170 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2020 | 57 | 0.170 |
Why?
|
| Hospitalization | 3 | 2024 | 1293 | 0.170 |
Why?
|
| Multimodal Imaging | 1 | 2020 | 64 | 0.170 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2020 | 588 | 0.160 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2021 | 194 | 0.160 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2019 | 33 | 0.160 |
Why?
|
| Mice, Nude | 4 | 2014 | 259 | 0.160 |
Why?
|
| Receptor, TIE-2 | 3 | 2011 | 7 | 0.160 |
Why?
|
| Radiologists | 1 | 2020 | 80 | 0.160 |
Why?
|
| Calcinosis | 1 | 2020 | 79 | 0.160 |
Why?
|
| Promoter Regions, Genetic | 2 | 2021 | 652 | 0.160 |
Why?
|
| Transcriptome | 1 | 2022 | 341 | 0.160 |
Why?
|
| Workload | 1 | 2020 | 118 | 0.160 |
Why?
|
| Sensitivity and Specificity | 3 | 2012 | 1097 | 0.160 |
Why?
|
| Calcium-Binding Proteins | 1 | 2019 | 87 | 0.160 |
Why?
|
| Efficiency, Organizational | 1 | 2020 | 93 | 0.160 |
Why?
|
| Treatment Outcome | 9 | 2024 | 5287 | 0.160 |
Why?
|
| Ultrasonography, Interventional | 1 | 2020 | 92 | 0.160 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2020 | 256 | 0.160 |
Why?
|
| Algorithms | 1 | 2024 | 979 | 0.160 |
Why?
|
| Radiopharmaceuticals | 2 | 2022 | 181 | 0.160 |
Why?
|
| Young Adult | 5 | 2017 | 4274 | 0.150 |
Why?
|
| Neural Stem Cells | 2 | 2016 | 43 | 0.150 |
Why?
|
| Inflammation | 2 | 2024 | 1099 | 0.150 |
Why?
|
| Blood-Brain Barrier | 1 | 2019 | 81 | 0.150 |
Why?
|
| Vitamin B 12 | 1 | 2018 | 13 | 0.150 |
Why?
|
| Mitochondrial Diseases | 1 | 2018 | 20 | 0.150 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2020 | 167 | 0.150 |
Why?
|
| Leukoencephalopathies | 1 | 2018 | 24 | 0.150 |
Why?
|
| Intubation, Intratracheal | 1 | 2020 | 194 | 0.150 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2018 | 124 | 0.150 |
Why?
|
| Spinal Cord Diseases | 1 | 2018 | 39 | 0.150 |
Why?
|
| Diagnostic Imaging | 1 | 2021 | 244 | 0.140 |
Why?
|
| Aged, 80 and over | 7 | 2024 | 5126 | 0.140 |
Why?
|
| Metabolic Diseases | 1 | 2018 | 54 | 0.140 |
Why?
|
| Oxides | 2 | 2007 | 33 | 0.140 |
Why?
|
| Carcinogenesis | 1 | 2018 | 118 | 0.140 |
Why?
|
| Diagnostic Errors | 1 | 2018 | 94 | 0.140 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 276 | 0.140 |
Why?
|
| Remission Induction | 3 | 2016 | 137 | 0.140 |
Why?
|
| Adenosine Deaminase | 1 | 2017 | 17 | 0.140 |
Why?
|
| Genetic Therapy | 3 | 2024 | 733 | 0.140 |
Why?
|
| Excitatory Amino Acid Transporter 2 | 1 | 2016 | 4 | 0.130 |
Why?
|
| Embolization, Therapeutic | 1 | 2020 | 309 | 0.130 |
Why?
|
| Iron | 2 | 2007 | 136 | 0.130 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2018 | 328 | 0.130 |
Why?
|
| Adenosine | 1 | 2017 | 70 | 0.130 |
Why?
|
| Adrenoleukodystrophy | 1 | 2016 | 8 | 0.130 |
Why?
|
| Transplantation Conditioning | 2 | 2016 | 98 | 0.130 |
Why?
|
| Cell Cycle Proteins | 1 | 2018 | 385 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 58 | 0.130 |
Why?
|
| Induction Chemotherapy | 1 | 2016 | 31 | 0.130 |
Why?
|
| Atrophy | 1 | 2016 | 76 | 0.130 |
Why?
|
| Carbon Radioisotopes | 3 | 2024 | 12 | 0.130 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2015 | 12 | 0.130 |
Why?
|
| Astrocytes | 1 | 2016 | 116 | 0.130 |
Why?
|
| Computer Simulation | 1 | 2018 | 459 | 0.120 |
Why?
|
| Lung | 1 | 2020 | 920 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 3 | 2012 | 737 | 0.120 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2015 | 39 | 0.120 |
Why?
|
| Adolescent | 3 | 2017 | 5851 | 0.120 |
Why?
|
| Spinal Cord | 1 | 2016 | 195 | 0.120 |
Why?
|
| Monocytes | 2 | 2008 | 345 | 0.120 |
Why?
|
| Apoferritins | 1 | 2014 | 1 | 0.120 |
Why?
|
| Neuroaxonal Dystrophies | 1 | 2014 | 1 | 0.120 |
Why?
|
| Iron Metabolism Disorders | 1 | 2014 | 1 | 0.120 |
Why?
|
| Psychomotor Disorders | 1 | 2014 | 7 | 0.120 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2024 | 276 | 0.120 |
Why?
|
| Disease-Free Survival | 5 | 2017 | 228 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 5 | 2018 | 3236 | 0.110 |
Why?
|
| Case-Control Studies | 2 | 2016 | 1055 | 0.110 |
Why?
|
| Transplantation, Autologous | 3 | 2022 | 120 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2021 | 300 | 0.110 |
Why?
|
| Myeloid Cells | 2 | 2013 | 89 | 0.110 |
Why?
|
| Meglumine | 1 | 2014 | 18 | 0.110 |
Why?
|
| Nitroimidazoles | 1 | 2013 | 3 | 0.110 |
Why?
|
| Adnexal Diseases | 1 | 2013 | 8 | 0.110 |
Why?
|
| Organometallic Compounds | 1 | 2014 | 63 | 0.110 |
Why?
|
| Vincristine | 3 | 2020 | 25 | 0.110 |
Why?
|
| Methionine | 2 | 2024 | 53 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2013 | 92 | 0.100 |
Why?
|
| Green Fluorescent Proteins | 3 | 2012 | 354 | 0.100 |
Why?
|
| Cerebellar Neoplasms | 1 | 2012 | 9 | 0.100 |
Why?
|
| Medulloblastoma | 1 | 2012 | 11 | 0.100 |
Why?
|
| Williams Syndrome | 1 | 2012 | 4 | 0.100 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2011 | 62 | 0.100 |
Why?
|
| Gene Expression Profiling | 2 | 2013 | 720 | 0.100 |
Why?
|
| Injections | 1 | 2012 | 76 | 0.100 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2012 | 29 | 0.100 |
Why?
|
| Growth Disorders | 1 | 2012 | 28 | 0.090 |
Why?
|
| Memory Disorders | 1 | 2012 | 48 | 0.090 |
Why?
|
| Angiopoietin-2 | 1 | 2011 | 3 | 0.090 |
Why?
|
| Gerstmann-Straussler-Scheinker Disease | 1 | 2010 | 1 | 0.090 |
Why?
|
| Reflex, Abnormal | 1 | 2010 | 3 | 0.090 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2022 | 45 | 0.090 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2011 | 49 | 0.090 |
Why?
|
| Neural Conduction | 1 | 2010 | 29 | 0.090 |
Why?
|
| Ferrosoferric Oxide | 2 | 2007 | 17 | 0.090 |
Why?
|
| Prions | 1 | 2010 | 23 | 0.090 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 75 | 0.090 |
Why?
|
| Iduronidase | 1 | 2010 | 5 | 0.090 |
Why?
|
| Mucopolysaccharidosis I | 1 | 2010 | 7 | 0.090 |
Why?
|
| Central Nervous System | 2 | 2024 | 193 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2014 | 1188 | 0.090 |
Why?
|
| Arachnoid Cysts | 1 | 2010 | 5 | 0.090 |
Why?
|
| Syringomyelia | 1 | 2010 | 3 | 0.090 |
Why?
|
| Cell Proliferation | 2 | 2018 | 942 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2010 | 57 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2015 | 697 | 0.080 |
Why?
|
| Spinal Cord Compression | 1 | 2010 | 28 | 0.080 |
Why?
|
| Macrophages | 2 | 2013 | 1015 | 0.080 |
Why?
|
| ErbB Receptors | 1 | 2010 | 112 | 0.080 |
Why?
|
| Cyclophosphamide | 2 | 2020 | 75 | 0.080 |
Why?
|
| Cell Line | 1 | 2014 | 1984 | 0.080 |
Why?
|
| Prednisone | 2 | 2020 | 85 | 0.080 |
Why?
|
| Genes, Reporter | 2 | 2007 | 241 | 0.080 |
Why?
|
| Doxorubicin | 2 | 2020 | 97 | 0.080 |
Why?
|
| Immunologic Factors | 1 | 2010 | 103 | 0.080 |
Why?
|
| Immunity, Innate | 2 | 2013 | 774 | 0.080 |
Why?
|
| Lower Extremity | 1 | 2010 | 153 | 0.080 |
Why?
|
| Receptors, GABA-A | 1 | 2009 | 23 | 0.080 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 2341 | 0.080 |
Why?
|
| Apoptosis | 1 | 2014 | 1033 | 0.080 |
Why?
|
| Central Nervous System Diseases | 1 | 2009 | 56 | 0.080 |
Why?
|
| Visual Acuity | 1 | 2009 | 117 | 0.080 |
Why?
|
| Lentivirus | 2 | 2024 | 63 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2008 | 99 | 0.070 |
Why?
|
| Disease Progression | 2 | 2014 | 1119 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 934 | 0.070 |
Why?
|
| Echo-Planar Imaging | 1 | 2007 | 33 | 0.070 |
Why?
|
| Recovery of Function | 2 | 2021 | 272 | 0.070 |
Why?
|
| Injections, Intravenous | 1 | 2007 | 155 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 396 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2013 | 618 | 0.070 |
Why?
|
| Mice, Transgenic | 4 | 2014 | 1206 | 0.060 |
Why?
|
| Conjunctival Diseases | 1 | 2006 | 2 | 0.060 |
Why?
|
| Orbital Diseases | 1 | 2006 | 9 | 0.060 |
Why?
|
| Staining and Labeling | 1 | 2007 | 124 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2010 | 1286 | 0.060 |
Why?
|
| Cell Lineage | 1 | 2007 | 259 | 0.060 |
Why?
|
| Helicobacter Infections | 1 | 2006 | 55 | 0.060 |
Why?
|
| Infant | 1 | 2010 | 1493 | 0.060 |
Why?
|
| Helicobacter pylori | 1 | 2006 | 58 | 0.060 |
Why?
|
| Pericytes | 1 | 2005 | 15 | 0.060 |
Why?
|
| Cell Differentiation | 3 | 2018 | 1304 | 0.060 |
Why?
|
| Stomach Neoplasms | 1 | 2006 | 69 | 0.060 |
Why?
|
| Child, Preschool | 1 | 2010 | 1794 | 0.060 |
Why?
|
| Cerebrospinal Fluid | 2 | 2018 | 19 | 0.060 |
Why?
|
| Angiography | 1 | 2005 | 145 | 0.060 |
Why?
|
| Behavior, Animal | 2 | 2017 | 215 | 0.060 |
Why?
|
| Switzerland | 2 | 2016 | 14 | 0.060 |
Why?
|
| Racemethionine | 1 | 2024 | 1 | 0.060 |
Why?
|
| Survival Rate | 2 | 2020 | 801 | 0.060 |
Why?
|
| Carotid Stenosis | 1 | 2005 | 104 | 0.060 |
Why?
|
| Temporal Lobe | 1 | 2024 | 46 | 0.050 |
Why?
|
| Cerebral Hemorrhage | 1 | 2024 | 85 | 0.050 |
Why?
|
| Seizures | 1 | 2024 | 113 | 0.050 |
Why?
|
| Brain Stem | 1 | 2002 | 28 | 0.050 |
Why?
|
| Aspartic Acid | 1 | 2002 | 28 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2018 | 474 | 0.050 |
Why?
|
| Huntington Disease | 1 | 2004 | 146 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2017 | 805 | 0.050 |
Why?
|
| Mice, Knockout | 3 | 2012 | 1997 | 0.050 |
Why?
|
| Radiography, Thoracic | 1 | 2023 | 111 | 0.050 |
Why?
|
| Skull Base | 1 | 2021 | 13 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2002 | 291 | 0.050 |
Why?
|
| Nasal Mucosa | 1 | 2021 | 18 | 0.050 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 178 | 0.050 |
Why?
|
| Smell | 1 | 2021 | 26 | 0.050 |
Why?
|
| Edema | 1 | 2021 | 42 | 0.040 |
Why?
|
| Ligands | 2 | 2015 | 411 | 0.040 |
Why?
|
| Neck | 1 | 2021 | 46 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 292 | 0.040 |
Why?
|
| High-Energy Shock Waves | 1 | 2020 | 4 | 0.040 |
Why?
|
| Injections, Intra-Articular | 1 | 2020 | 48 | 0.040 |
Why?
|
| Steroids | 1 | 2020 | 52 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 193 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2011 | 284 | 0.040 |
Why?
|
| Genetic Vectors | 3 | 2013 | 808 | 0.040 |
Why?
|
| Heterografts | 1 | 2019 | 61 | 0.040 |
Why?
|
| CD13 Antigens | 1 | 2019 | 4 | 0.040 |
Why?
|
| Cell Membrane Permeability | 1 | 2019 | 39 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2011 | 186 | 0.040 |
Why?
|
| Health Personnel | 1 | 2022 | 342 | 0.040 |
Why?
|
| Cell Self Renewal | 1 | 2018 | 11 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2019 | 132 | 0.040 |
Why?
|
| Salvage Therapy | 2 | 2011 | 71 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 674 | 0.040 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2018 | 51 | 0.040 |
Why?
|
| Age of Onset | 1 | 2018 | 170 | 0.040 |
Why?
|
| Gadolinium DTPA | 1 | 2018 | 85 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2014 | 2095 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 851 | 0.030 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2019 | 205 | 0.030 |
Why?
|
| Behavior | 1 | 2017 | 36 | 0.030 |
Why?
|
| Length of Stay | 1 | 2020 | 779 | 0.030 |
Why?
|
| Patch-Clamp Techniques | 1 | 2016 | 127 | 0.030 |
Why?
|
| Intraocular Lymphoma | 1 | 2016 | 1 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2020 | 831 | 0.030 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2016 | 2 | 0.030 |
Why?
|
| Mucositis | 1 | 2016 | 7 | 0.030 |
Why?
|
| Denmark | 1 | 2016 | 16 | 0.030 |
Why?
|
| Heart Injuries | 1 | 2016 | 17 | 0.030 |
Why?
|
| Cerebral Infarction | 1 | 2016 | 76 | 0.030 |
Why?
|
| Germany | 1 | 2016 | 52 | 0.030 |
Why?
|
| Anisotropy | 1 | 2016 | 58 | 0.030 |
Why?
|
| Glutamic Acid | 1 | 2016 | 95 | 0.030 |
Why?
|
| Gray Matter | 1 | 2016 | 31 | 0.030 |
Why?
|
| United Kingdom | 1 | 2016 | 66 | 0.030 |
Why?
|
| Transplantation, Heterologous | 2 | 2007 | 223 | 0.030 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2016 | 20 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2018 | 2901 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2016 | 45 | 0.030 |
Why?
|
| Death, Sudden | 1 | 2016 | 28 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2020 | 421 | 0.030 |
Why?
|
| Poisoning | 1 | 2016 | 31 | 0.030 |
Why?
|
| Histocompatibility Testing | 1 | 2015 | 31 | 0.030 |
Why?
|
| Research Design | 1 | 2019 | 556 | 0.030 |
Why?
|
| Liver | 1 | 2020 | 796 | 0.030 |
Why?
|
| Neutropenia | 1 | 2016 | 62 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2016 | 69 | 0.030 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2016 | 41 | 0.030 |
Why?
|
| Hospital Mortality | 1 | 2020 | 845 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2016 | 45 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2012 | 1469 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 69 | 0.030 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2015 | 38 | 0.030 |
Why?
|
| Mice, SCID | 2 | 2007 | 513 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2016 | 365 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2016 | 98 | 0.030 |
Why?
|
| Neuronal Plasticity | 1 | 2016 | 141 | 0.030 |
Why?
|
| Quality of Life | 1 | 2022 | 1138 | 0.030 |
Why?
|
| Autoradiography | 1 | 2015 | 53 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2016 | 197 | 0.030 |
Why?
|
| Metabolome | 1 | 2015 | 27 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2016 | 201 | 0.030 |
Why?
|
| White Matter | 1 | 2016 | 114 | 0.030 |
Why?
|
| Anemia | 1 | 2016 | 119 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2018 | 1555 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2015 | 287 | 0.030 |
Why?
|
| Acute Kidney Injury | 1 | 2016 | 132 | 0.030 |
Why?
|
| Thrombosis | 1 | 2016 | 183 | 0.030 |
Why?
|
| Gene Order | 1 | 2013 | 29 | 0.030 |
Why?
|
| Cell Death | 1 | 2014 | 271 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2013 | 59 | 0.030 |
Why?
|
| Hippocampus | 1 | 2014 | 247 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2012 | 43 | 0.030 |
Why?
|
| DNA Damage | 1 | 2014 | 279 | 0.030 |
Why?
|
| Chile | 1 | 2012 | 12 | 0.030 |
Why?
|
| Spain | 1 | 2012 | 32 | 0.030 |
Why?
|
| Brain Ischemia | 1 | 2016 | 399 | 0.020 |
Why?
|
| Rhombencephalon | 1 | 2012 | 7 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 194 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 2517 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2013 | 359 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2013 | 234 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2013 | 554 | 0.020 |
Why?
|
| Time Factors | 2 | 2010 | 3621 | 0.020 |
Why?
|
| Exploratory Behavior | 1 | 2012 | 33 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 188 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2012 | 230 | 0.020 |
Why?
|
| Mutagenesis, Insertional | 1 | 2012 | 89 | 0.020 |
Why?
|
| Organ Size | 1 | 2012 | 165 | 0.020 |
Why?
|
| Adenoma, Islet Cell | 1 | 2011 | 4 | 0.020 |
Why?
|
| Fear | 1 | 2012 | 65 | 0.020 |
Why?
|
| Heterozygote | 1 | 2012 | 162 | 0.020 |
Why?
|
| Muscle Fatigue | 1 | 2012 | 47 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 591 | 0.020 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2010 | 8 | 0.020 |
Why?
|
| Electrophysiological Phenomena | 1 | 2010 | 20 | 0.020 |
Why?
|
| Evoked Potentials, Motor | 1 | 2010 | 20 | 0.020 |
Why?
|
| Neuroendocrine Tumors | 1 | 2011 | 21 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 2012 | 133 | 0.020 |
Why?
|
| Tyrphostins | 1 | 2010 | 3 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2010 | 52 | 0.020 |
Why?
|
| Proline | 1 | 2010 | 42 | 0.020 |
Why?
|
| Quinazolines | 1 | 2010 | 21 | 0.020 |
Why?
|
| Stiff-Person Syndrome | 1 | 2010 | 1 | 0.020 |
Why?
|
| Paraparesis, Spastic | 1 | 2010 | 1 | 0.020 |
Why?
|
| Procarbazine | 1 | 2010 | 3 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 645 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2014 | 1128 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 2010 | 19 | 0.020 |
Why?
|
| Leucine | 1 | 2010 | 61 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2012 | 293 | 0.020 |
Why?
|
| Cell Communication | 1 | 2011 | 124 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 1505 | 0.020 |
Why?
|
| Contraindications | 1 | 2010 | 46 | 0.020 |
Why?
|
| Cranial Irradiation | 1 | 2010 | 10 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2010 | 23 | 0.020 |
Why?
|
| Cell Movement | 1 | 2012 | 428 | 0.020 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2010 | 10 | 0.020 |
Why?
|
| Spinal Canal | 1 | 2010 | 5 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2010 | 81 | 0.020 |
Why?
|
| Subarachnoid Space | 1 | 2010 | 10 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2010 | 135 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2010 | 61 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2013 | 461 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 810 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 185 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2011 | 448 | 0.020 |
Why?
|
| Decompression, Surgical | 1 | 2010 | 61 | 0.020 |
Why?
|
| Autoantibodies | 1 | 2010 | 172 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2010 | 137 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2010 | 193 | 0.020 |
Why?
|
| Gliosis | 1 | 2009 | 27 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 2383 | 0.020 |
Why?
|
| Demyelinating Diseases | 1 | 2009 | 16 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2013 | 621 | 0.020 |
Why?
|
| Family | 1 | 2010 | 229 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2009 | 217 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2010 | 180 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2009 | 226 | 0.020 |
Why?
|
| Recurrence | 1 | 2010 | 603 | 0.020 |
Why?
|
| Hematopoiesis | 1 | 2008 | 120 | 0.020 |
Why?
|
| Diffusion | 1 | 2008 | 82 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2010 | 303 | 0.020 |
Why?
|
| Brain Tissue Transplantation | 1 | 2007 | 5 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2010 | 378 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 916 | 0.020 |
Why?
|
| Magnetics | 1 | 2007 | 53 | 0.020 |
Why?
|
| Wound Healing | 1 | 2008 | 174 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2008 | 228 | 0.020 |
Why?
|
| Phenotype | 1 | 2010 | 1138 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 678 | 0.020 |
Why?
|
| Gastroscopy | 1 | 2006 | 20 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 1553 | 0.020 |
Why?
|
| Mesoderm | 1 | 2005 | 81 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 496 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 2006 | 260 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2010 | 605 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 209 | 0.010 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2005 | 131 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2013 | 1118 | 0.010 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2005 | 178 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2010 | 1204 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2005 | 275 | 0.010 |
Why?
|
| Medulla Oblongata | 1 | 2002 | 7 | 0.010 |
Why?
|
| Choline | 1 | 2002 | 20 | 0.010 |
Why?
|
| Creatine | 1 | 2002 | 24 | 0.010 |
Why?
|
| Pons | 1 | 2002 | 15 | 0.010 |
Why?
|
| Mesencephalon | 1 | 2002 | 25 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2005 | 1028 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2005 | 331 | 0.010 |
Why?
|
| Reference Values | 1 | 2002 | 326 | 0.010 |
Why?
|